axinn

Axinn Successful in Protecting Client Alvogen's Entry to Drug Market

NEWS | 1 MIN READ

March 1, 2012

Axinn obtained a favorable decision for its client, Alvogen, Inc., which allows Alvogen's valuable generic version of the antibiotic Vancocin[®] to remain on the market. ViroPharma, Inc. brought the case against the U.S. Food and Drug Administration to reverse the approval of three Abbreviated New Drug Applications, asking for a preliminary injunction that would have forced Alvogen's and two other pharmaceutical companies' generic versions of Vancocin off the market. U.S. District Judge Ellen Segal Huvelle ruled against ViroPharma, denying the company's bid to maintain the monopoly on Vancocin – ViroPharma's highest-selling drug – during the pendency of the case.

Within less than a week, the Axinn team successfully moved to intervene, submitted opposition papers and argued before Judge Huvelle at a hearing held on April 19. The Court denied ViroPharma's motion days later, on April 23, 2012. The Axinn team included Nick Gaglio.

The case is *ViroPharma Inc. v. Hamburg*, 12-cv-584, U.S. District Court for the District of Columbia (Washington).

Related People

Nicholas E.O. Gaglio



Related Services

Intellectual Property

To subscribe to our publications, click here.

Featured Insights

- GCR Live: Law Leaders Europe 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
 WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts Champions of the Arts Awards and Gala 2025
 SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies Making Paragraph IV Litigation Work for You

WEBINAR INTELLECTUAL PROPERTY

- Informa CompLaw Antitrust West Coast Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
 AXINN VIEWPOINTS LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved